Initial high-efficacy disease-modifying therapy in multiple sclerosis
Mathias Due Buron(Rigshospitalet), Melinda Magyari(University of Copenhagen), Viktoria Papp(Copenhagen University Hospital), Matthias Kant(Sygehus Sønderjylland), Zsolt Illés(Universität Hamburg), Henrik Boye Jensen(Region of Southern Denmark), Ismael Barzinji, Ásta Theódórsdóttir(Rigshospitalet), Peter Vestergaard Rasmussen(Aarhus University Hospital), Per Soelberg Sørensen(University of Copenhagen), Jeppe Romme Christensen(Aarhus University Hospital), Arkadiusz Wêglewski(Rigshospitalet), Thor Ameri Chalmer(Rigshospitalet), Thor Petersen(Aarhus University Hospital), Finn Sellebjerg(Danish Multiple Sclerosis Center)
Cited by 160
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
|Science|2019|1.4k
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
|The Lancet|2001|1.1k
Multiple Sclerosis Severity Score
|Neurology|2005|957